Breaking News

ABL Acquisition Extends Ardena’s Early-phase Offering

Broadens the CDMO’s pre-clinical and clinical offering to include bioanalytical and drug discovery services.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Early-phase contract development and manufacturing organization (CDMO), Ardena, has acquired bioanalytical contract laboratory, Analytical Biochemical Laboratory (ABL). The acquisition of Netherlands-based ABL follows the merging of Pharmavize and Crystallics to form Ardena and broadens the CDMO’s pre-clinical and clinical offering to include bioanalytical and drug discovery services. With the addition of ABL, the Ardena Group now employs 125 scientists. “Our focus is to help customers ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters